NCT02983019 (FLU-EE) is a clinical trial of Kagocel in Influenza, sponsored by Nearmedic Plus LLC.

Who is sponsoring NCT02983019?

NCT02983019 is sponsored by Nearmedic Plus LLC.

What drugs are being tested in NCT02983019?

Interventions in NCT02983019: Kagocel.

What condition does NCT02983019 study?

NCT02983019 studies Influenza, Acute Upper Respiratory Infection.

Is NCT02983019 still recruiting?

NCT02983019 is currently completed. Last updated 16 February 2017.

Last reviewed 2017-02-16 · How we verify

NCT02983019: FLU-EE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-interventional Study: Treatment of Influenza in Routine Clinical Practice (FLU-EE)

Completed Last updated 16 February 2017

What this trial tests

trial testing Kagocel in Influenza in 18,946 participants. Completed in 1 September 2016.

Timeline

1 December 2013

Primary endpoint
1 December 2015

1 September 2016

Quick facts

Lead sponsor	Nearmedic Plus LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18,946
Start date	1 December 2013
Primary completion	1 December 2015
Estimated completion	1 September 2016
Sites	4 locations across Armenia, Georgia, Moldova, Russia

Drugs / interventions tested

Kagocel — full drug profile →

Conditions studied

Influenza — all drugs for Influenza →
Acute Upper Respiratory Infection — all drugs for Acute Upper Respiratory Infection →

Sponsor

Nearmedic Plus LLC — full company profile →

Who can join

Adults 18 to 100, any sex, with Influenza or Acute Upper Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The socio-demographic data and symptoms of disease in the joint population of patients with influenza and influenza-like illness caused by different types of viruses
Time frame: up to 14 days
socio-demographic data, symptoms of disease
The treatment description: names of drugs, dose, time of administration with regards to disease onset ("early" - from 1 to 3 days of symptoms; "late" - 4 or more days of symptoms)
Time frame: up to 14 days
The efficacy (yes or no) of the treatment schemas with regards to severity of disease (mild, moderate, severe)
Time frame: up to 14 days
Frequency of influenza complications with antibacterial drugs administration requirement
Time frame: up to 14 days

Sponsor's own description

This study evaluates the statistics of influenza and acute respiratory viral infections (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology: disease severity and bacterial exacerbations; patients demography; treatment duration and timelines; safety; quality of treatment) in routine clinical practice with focus on drug therapy and usage of interferons' inducers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Kagocel

Trials testing the same drug.

NCT04626622 — Kagocel® for the Prevention of ARVI and Influenza in Young People · completed
NCT04611061 — Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers · completed
NCT04651491 — Treatment of Influenza and ARVI in Children by Kagocel ® · completed

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other Nearmedic Plus LLC trials

Trials by the same sponsor.

NCT04150224 — Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169 · Phase 1 · completed
NCT04626622 — Kagocel® for the Prevention of ARVI and Influenza in Young People · completed
NCT04664127 — Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyc · completed
NCT03677258 — Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy · NA · completed
NCT04611061 — Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02983019 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nearmedic Plus LLC
Last refreshed: 16 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02983019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing